Treatment News : Two New Therapies Successfully Treat Gonorrhea

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » July 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


July 16, 2013

Two New Therapies Successfully Treat Gonorrhea

The Centers for Disease Control and Prevention (CDC) and the National Institutes for Health (NIH) have announced that two new antibiotic therapies are highly effective at treating gonorrhea. The sexually transmitted infection (STI) has developed resistance to nearly all the current arsenal of treatments, increasing the need for new lines of attack. However, participants in the clinical trials of the new antibiotics reported significant side effects, most notably gastrointestinal problems, so the CDC is not currently changing its treatment guidelines for the STI.

The National Institute of Allergy and Infectious Diseases, a division of the NIH, sponsored a Phase IV clinical trial of two therapies; the first included injectable gentamicin in combination with oral azithromycin, and the second was oral gemifloxacin in combination with oral azithromycin. The trial began in 2010, enrolling 401 participants who were between the ages of 15 and 60 and who had an untreated gonorrhea infection.

The injectable gentamicin/oral azithormycin combination was 100 percent effective at curing gonorrhea, while the oral gemifloxacin/oral azithromycin therapy was 99.5 percent effective. Out of the 202 participants who took gentamicin/azithormycin, 28 percent experienced nausea, 19 percent diarrhea and 7 percent either abdominal discomfort or pain or vomiting. Out of the 199 participants in the gemifloxacin/azithromycin arm of the study, 27 percent experienced nausea, 23 percent diarrhea and 11 percent abdominal pain or discomfort.

“These trial results are an exciting step in the right direction in the fight against drug-resistant gonorrhea,” Gail Bolan, MD, director of the CDC’s Division of STD Prevention, said in a release. “But patients need more oral options with fewer side effects. It is imperative that researchers and pharmaceutical companies prioritize research to continue to identify new, effective, better-tolerated drugs and drug combinations.”

To read the CDC press release, click here.

Search: Gonorrhea, CDC, NIH, sexually transmitted infection, STI, Centers for Disease Control and Prevention, National Institutes for Health, azithormycin, gentamicin, gemifloxacin, Gail Bolan.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.